Mumps is a transmissible disease caused by
the mumps virus and is characterized by swelling of glands in neck and face.
Some of the symptoms of this disease are headache, fever, tiredness, loss of
appetite, and muscle ache.
Request
to Get Sample Pages at: https://www.pharmaproff.com/request-sample/1067
The disease
can be transferred from an infected person through coughing; sneezing; and
sharing items, such as razors and utensils. According to the Centers for
Disease Control and Prevention, a study from January 2017 to July 2017 covering
46 states of the U.S., estimated that around 3,886 people have mumps infection.
Make
Enquiry Before Buying the Report:https://www.pharmaproff.com/enquiry/1067
The
complications associated with mumps include encephalitis, orchitis, mastitis,
meningitis, and deafness. Daiichi Sankyo Co. Ltd. is in the process of
developing VN-0102 as a measles-mumps-rubella vaccine for the treatment of
mumps. Cadila Healthcare Limited is also involved in the development of drug
candidates for the treatment of this disease.
Access
Detailed Report Summary: https://www.pharmaproff.com/report/mumps-therapeutics-pipeline-analysis
The report
provides a comprehensive understanding of the pipeline activities covering all
drug candidates under various stages of development, with the detailed analysis
of pipeline and clinical trials.
Pipeline
analysis of drugs by phases includes product description and development
activities including information about clinical results, designations,
collaborations, licensing, grants, technology, and others.
No comments:
Post a Comment